UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 757

Sortiert nach

Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool

Pharmaceutics, 2020-07, Vol.12 (7), p.672

2020

Volltextzugriff (PDF)

Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models

Pharmaceutics, 2017-09, Vol.9 (4), p.41

2017

Volltextzugriff (PDF)

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

Journal of medicinal chemistry, 2018-03, Vol.61 (6), p.2227-2245

2018

Volltextzugriff (PDF)

Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature

Clinical and translational science, 2024-01, Vol.17 (1), p.e13676-n/a

2024

Volltextzugriff (PDF)

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

Journal of medicinal chemistry, 2012-05, Vol.55 (9), p.4101-4113

2012

Volltextzugriff (PDF)

Which Physicians Are Taking Care of People With COPD?

Chest, 2019-04, Vol.155 (4), p.771-777

2019

Volltextzugriff (PDF)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)

BMC cancer, 2022-04, Vol.22 (1), p.468-468, Article 468

2022

Volltextzugriff (PDF)

Discovery DMPK Quick Guide: Guide to Data Interpretation and Integration

1, 2022

Volltextzugriff (PDF)

Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy

The Journal of pharmacology and experimental therapeutics, 2011-07, Vol.338 (1), p.154

2011

Volltextzugriff (PDF)

Prognostic value of visually detected coronary artery calcification on unenhanced non-gated thoracic computed tomography for prediction of non-fatal myocardial infarction and all-cause mortality

Journal of cardiovascular computed tomography, 2017-05, Vol.11 (3), p.196-202

2017

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

Clinical cancer research, 2011-07, Vol.17 (14), p.4682-4692

2011

Volltextzugriff (PDF)

Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists

Bioorganic & medicinal chemistry letters, 2015-08, Vol.25 (15), p.2907-2912

2015

Volltextzugriff (PDF)

Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment

Frontiers in pharmacology, 2024-03, Vol.15, p.1358393-1358393

2024

Volltextzugriff (PDF)

Discovery of VIP236, an αvβ3-Targeted Small-Molecule–Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors

Cancers, 2023-09, Vol.15 (17), p.4381

2023

Volltextzugriff (PDF)

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Clinical cancer research, 2012-06, Vol.18 (11), p.3090-3099

2012

Volltextzugriff (PDF)

Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc

Bioorganic & medicinal chemistry letters, 2013-12, Vol.23 (24), p.6604-6609

2013

Volltextzugriff (PDF)

Trends in non-receipt of recommended COPD medication

ERJ open research, 2022-04, Vol.8 (2), p.584

2022

Volltextzugriff (PDF)

Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834

Bioorganic & medicinal chemistry letters, 2015-03, Vol.25 (6), p.1333-1337

2015

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates

Clinical pharmacokinetics, 2015-01, Vol.54 (1), p.81-93

2015

Volltextzugriff (PDF)

Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor

Drug metabolism and disposition, 2011-10, Vol.39 (10), p.1840

2011

Volltextzugriff (PDF)

Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941

Drug metabolism and disposition, 2010-09, Vol.38 (9), p.1436

2010

Volltextzugriff (PDF)

A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types

Cancers, 2022-01, Vol.14 (2), p.391

2022

Volltextzugriff (PDF)

Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties

Bioorganic & medicinal chemistry letters, 2016-09, Vol.26 (18), p.4455-4461

2016

Volltextzugriff (PDF)

Investigation of the Rat Model for Preclinical Evaluation of pH-Dependent Oral Absorption in Humans

Molecular pharmaceutics, 2013-11, Vol.10 (11), p.3997-4004

2013

Volltextzugriff (PDF)

1 – 25 von 757

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(684)
Mit Volltextzugriff
(677)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool

Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

Which Physicians Are Taking Care of People With COPD?

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)

Discovery DMPK Quick Guide: Guide to Data Interpretation and Integration

Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy

Prognostic value of visually detected coronary artery calcification on unenhanced non-gated thoracic computed tomography for prediction of non-fatal myocardial infarction and all-cause mortality

Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists

Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment

Discovery of VIP236, an αvβ3-Targeted Small-Molecule–Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc

Trends in non-receipt of recommended COPD medication

Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834

Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates

Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor

Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941

A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types

Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties

Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Investigation of the Rat Model for Preclinical Evaluation of pH-Dependent Oral Absorption in Humans

Suchergebnisse filtern